Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer

University of California, San Francisco Carol Franc Buck Breast Care Center, San Francisco, USA.
Breast Cancer Research and Treatment (Impact Factor: 4.2). 09/2007; 105(1):17-28. DOI: 10.1007/s10549-006-9430-6
Source: PubMed

ABSTRACT Botanical therapies are often used by breast cancer patients yet few clinical trials have evaluated their safety and efficacy. We studied mechanisms of activity and performed a phase I clinical trial in patients with advanced breast cancer to evaluate BZL101, an aqueous extract from Scutellaria barbata.
Preclinical studies were conducted in vitro to characterize cell death induced by BZL101. In a phase I trial, eligible patients had histologically confirmed, measurable metastatic breast cancer. Treatment consisted of 350 ml per day of oral BZL101, administered as sole cancer therapy until disease progression, toxicity or personal preference to discontinue. Primary endpoints were safety, toxicity and tumor response.
BZL101 extract induced strong growth inhibition and apoptosis of breast cancer cell lines. In the phase I trial, 21 patients received BZL101. Mean age was 54 years (30-77) and mean number of prior treatments for metastatic disease was 3.9 (0-10). There were no grade III or IV adverse events (AEs). The most frequently reported BZL101-related grade I and II AEs included: nausea (38%), diarrhea (24%), headache (19%) flatulence (14%), vomiting (10%), constipation (10%), and fatigue (10%). Sixteen patients were evaluable for response. Four patients had stable disease (SD) for >90 days (25%) and 3/16 had SD for >180 days (19%). Five patients had objective tumor regression, one of which was 1 mm short of a PR based on RECIST criteria.
BZL 101 inhibits breast cancer cell lines by inducing apoptosis. In a phase I clinical trial, BZL101 was safe and had a favorable toxicity profile. BZL101 demonstrated encouraging clinical activity in this heavily pretreated population.

Download full-text


Available from: Hope Rugo, Jul 04, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Micropropagation protocols to minimize hyperhydricity were optimized for medicinal Scutellaria barbata and Scutellaria racemosa. Six cytokinins and eight different carbon sources at two differ-ent incubation periods of 14 and 21 days were studied for adventitious shoot bud induction using nodal explants. In S. barbata, 5 µM meta-Topolin and 0.1 µM NAA supplemented shoot induction medium produced four shoots each after 14 and 21 day incubation. Observation of S. racemosa nodal explants recorded four and five shoots after 14 and 21 day incubation. In both species, con-trol explants (no plant growth regulators in the medium) consistently resulted in the bud break with two shoots in both 14 and 21 day incubation. The effect of carbon source on shoot regenera-tion was studied by supplementing eight different sugars at 0.1 M concentration to the optimized shoot induction medium (5 µM meta-Topolin and 0.1 µM NAA). S. barbata nodal explants cultured on shoot induction medium supplemented with fructose and glucose for 14 days produced 10 and nine adventitious shoots respectively; and after 21 day incubation adventitious shoot count reached 19 in glucose supplemented medium. S. racemosa explants in the same experiment pro-duced five shoots in maltose and four shoots in sorbitol supplemented medium after 14 day incu-bation; whereas after 21 day incubation, sucrose and maltose produced five shoots; fructose, glu-cose, and sorbitol produced four shoots. Regenerated plants were successfully acclimatized and Scanning Electron Microscopy of the leaf surface revealed differences in stomatal behavior and cuticle deposition between in vitro and acclimatized plants. The antioxidant assay conducted on both Scutellaria species showed considerable total polyphenol content, TEAC activity and flavo-noid content in fresh and dried leaf samples attributing to their medicinal potential.
    American Journal of Plant Sciences 11/2014; 5(5):3662-3672. DOI:10.4236/ajps.2014.524382
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Within the genus Scutellaria various species are used in different folk medicines throughout Asia. Traditional Chinese Medicine (TCM) uses S. baicalensis (Labiatae) to treat various inflammatory conditions. The root shows strong anticancer properties in vitro and was suggested for clinical trials against multiple myeloma. Further, S. barbata was successfully tested against metastatic breast cancer in a phase I/II trial. Therefore, we investigated the anti-cancer properties of S. orientalis L. ssp. carica Edmondson, an endemic subspecies from the traditional medicinal plant S. orientalis L. in Turkey, which is used to promote wound healing and to stop haemorrhage. Freeze-dried plant material was extracted with petroleum ether, dichloromethane, ethyl acetate, and methanol and the bioactivity of these extracts was analysed by proliferation assay, cell death determination, and by investigating protein expression profiles specific for cell cycle arrest and apoptosis. The strongest anti-leukemic activity was shown by the methanol extract, which contained apigenin, baicalein, chrysin, luteolin and wogonin, with an IpC50 of 43 microg/ml (corresponding to 1.3mg/ml of dried plant material) which correlated with cyclin D1- and Cdc25A suppression and p21 induction. At 132 microg/ml (=4 mg/ml of the drug) this extract caused genotoxic stress indicated by substantial phosphorylation of the core histone H2AX (gamma-H2AX) followed by activation of caspase 3 and signature-type cleavage of PARP resulting in a 55% apoptosis rate after 48 hours of treatment. Here, we report for the first time that S. orientalis L. ssp. carica Edmondson exhibited potent anti-leukaemic properties likely through the anti-proliferative effect of baicalein and the genotoxic property of wogonin.
    Phytomedicine: international journal of phytotherapy and phytopharmacology 08/2009; 17(1):55-62. DOI:10.1016/j.phymed.2009.06.001 · 2.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Use of Chinese herbal medicines (CHM) by cancer patients is growing although scientific evidence on their safety and efficacy is limited. Method: A pilot study of CHM06, comprising 12 herbs, was conducted to assess the associated safety, tolerability and toxicity in cancer patients receiving chemotherapy. Patients with metastatic cancer who were about to receive a new line of chemotherapy started CHM06 a week prior to chemotherapy. Patients were assessed full blood counts and liver function were recorded at the commencement of CHM06, before each cycle, and at the end of cycle 3 chemotherapy for their toxicity, tolerability, and adverse events. Results: Of the 16 participants, 11 completed all 3 cycles of treatment and used 80% of the prescribed CHM. In the patients that completed the study, there was no significant difference in white blood cell (WBC), haemoglobin (Hb) and platelet counts after the use of CHM06 alone prior to commencement of chemotherapy. Fourteen patients tolerated the CHM06 well while tolerance was poor in 2 patients. Conclusion: This study suggests that CHM06 was well tolerated and accepted by patients undergoing chemotherapy. To further evaluate the safety and efficacy of CHM06 in conjunction with chemotherapy, randomised trials will be required.